Gieffers J, Solbach W, Maass M
Institute of Medical Microbiology and Hygiene, Medical University of Lübeck, Germany.
Cardiovasc Drugs Ther. 2001;15(3):259-62. doi: 10.1023/a:1011972424529.
Recovery of viable Chlamydia pneumoniae from atheromas of coronary heart diseases patients has initiated pilot studies to eradicate C. pneumoniae from vascular tissue by antibiotic treatment. To provide data for the selection of effective antibiotics, we investigated the in vitro activity of anti-chlamydial antibiotics to eliminate vascular strains of C. pneumoniae from coronary endothelial and smooth muscle cells, celltypes that are involved in the pathogenesis of atherosclerosis.
The susceptibility of the obligate intracellular chlamydiae was studied in primary coronary endothelial cells, smooth muscle cells and immortalized epithelial cells. Minimal inhibitory concentrations (MICs) were determined for ofloxacin, levofloxacin, trovafloxacin, moxifloxacin, erythromycin, azithromycin, roxithromycin, rifapentin and rifampin.
In vitro, rifampin was the most effective drug overall. Moxifloxacin and trovafloxacin were as effective as the macrolides of which roxithromycin was the most active one.
Actively replicating C. pneumoniae can be eliminated in vitro from cell types, involved in the pathogenesis of atherosclerosis by various antibiotics. These data provide an experimental background for the selection of antibiotics in clinical eradication studies and will help to assess the potential success of prevention and eradication therapies.
从冠心病患者的动脉粥样硬化斑块中分离出活的肺炎衣原体，这引发了通过抗生素治疗从血管组织中根除肺炎衣原体的初步研究。为了提供选择有效抗生素的数据，我们研究了抗衣原体抗生素对从冠状动脉内皮细胞和平滑肌细胞（参与动脉粥样硬化发病机制的细胞类型）中消除肺炎衣原体血管菌株的体外活性。
在原代冠状动脉内皮细胞、平滑肌细胞和永生化上皮细胞中研究专性细胞内衣原体的敏感性。测定了氧氟沙星、左氧氟沙星、曲伐沙星、莫西沙星、红霉素、阿奇霉素、罗红霉素、利福喷汀和利福平的最低抑菌浓度（MIC）。
在体外，利福平总体上是最有效的药物。莫西沙星和曲伐沙星与大环内酯类药物效果相当，其中罗红霉素活性最强。
通过各种抗生素可在体外从参与动脉粥样硬化发病机制的细胞类型中消除活跃复制的肺炎衣原体。这些数据为临床根除研究中抗生素的选择提供了实验背景，并将有助于评估预防和根除治疗的潜在成功率。
